Reuters: Regulatory News: Bayer seeks wider use for eye drug Eylea in Europe

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer seeks wider use for eye drug Eylea in Europe Nov 7th 2013, 11:15 FRANKFURT | Thu Nov 7, 2013 6:15am EST FRANKFURT Nov 7 (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema. Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales. The injection, which Bayer is co-developing with Regeneron , is already approved for other eye diseases.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions